Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasser Ged

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 4, 2025
Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell CarcinomaYasser Ged, Amina Touma, Luis Meza Contreras, et al.
Journal of Neuro-Oncology|December 12, 2025
Brain metastases from renal cell carcinoma: a large retrospective claims-based oncology cohort analysis of prevalence, chronicity, and survival outcomesMegan Parker, Austin Carmichael, Alyssa G Arbuiso, et al.
BMC Urology|July 4, 2020
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinationsYasser Ged, Ruby Gupta, Cihan Duzgol, et al.
Clinical Genitourinary Cancer|June 2, 2019
Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment OutcomesYasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Cell Reports. Medicine|February 22, 2023
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinomaJulie Stein Deutsch, Evan J Lipson, Ludmila Danilova, et al.
Cancer Research Communications|March 25, 2025
Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic SimilarityRoy Elias, Thomas Nirschl, Michael Rezaee, et al.
Clinical Genitourinary Cancer|May 1, 2019
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment OutcomesYasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
The Lancet. Oncology|December 25, 2019
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort studyAlejandro Sanchez, Helena Furberg, Fengshen Kuo, et al.
Nature Communications|August 22, 2020
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy responseA Ari Hakimi, Kyrollis Attalla, Renzo G DiNatale, et al.
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 4, 2025
Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell CarcinomaYasser Ged, Amina Touma, Luis Meza Contreras, et al.
Journal of Neuro-Oncology|December 12, 2025
Brain metastases from renal cell carcinoma: a large retrospective claims-based oncology cohort analysis of prevalence, chronicity, and survival outcomesMegan Parker, Austin Carmichael, Alyssa G Arbuiso, et al.
BMC Urology|July 4, 2020
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinationsYasser Ged, Ruby Gupta, Cihan Duzgol, et al.
Clinical Genitourinary Cancer|June 2, 2019
Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment OutcomesYasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Cell Reports. Medicine|February 22, 2023
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinomaJulie Stein Deutsch, Evan J Lipson, Ludmila Danilova, et al.
Cancer Research Communications|March 25, 2025
Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic SimilarityRoy Elias, Thomas Nirschl, Michael Rezaee, et al.
Clinical Genitourinary Cancer|May 1, 2019
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment OutcomesYasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
The Lancet. Oncology|December 25, 2019
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort studyAlejandro Sanchez, Helena Furberg, Fengshen Kuo, et al.
Nature Communications|August 22, 2020
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy responseA Ari Hakimi, Kyrollis Attalla, Renzo G DiNatale, et al.
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
Pageof 6